CVD is the leading cause of death in Australia and represents the nation’s largest disease burden.

Despite a common misconception that CVD is solely linked to lifestyle choices and largely resolved, it remains a significant and complex health issue. CVD can affect anyone—regardless of age, background, or lifestyle—and ongoing research and innovation are critical.

Australia has a world-class health and medical research sector, but continued investment is essential to maintain our momentum in tackling CVD. Without sustained funding, the sector cannot fully utilise its expertise or respond effectively to the growing challenges posed by CVD.

ACvA champions a national multidisciplinary approach to identify and close gaps in the most pressing areas of need and develop clear research priorities that will improve patient outcomes, ensuring Australia leads in life-saving discoveries, treatments, and health policy.

We advocate for a nationally coordinated cardiovascular research program that supports innovation from bench to bedside—spanning discovery, development, and delivery.

ACvA has 7 strategic flagships representing the capabilities across research spectrum: Disease Mechanisms, Drug Discovery & Translation, Biomedical Engineering, Precision Medicine, Clinical Trials, Big Data and Implementation & Policy.

These flagships conduct horizon scanning and set strategic priorities for investment in cardiovascular research to keep Australia at the forefront of tackling the CVD burden. Their insights shape ACvA’s advocacy agenda and amplify the voices of our members across the sector.